Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Musculoskeletal Pain Market Snapshot: Amrix is New Player in Field

Executive Summary

Cephalon's novel musculoskeletal treatment Amrix appears positioned to give King's Skelaxin a run for the money. For King, however, a possible "at-risk" generic launch in 2009 presents a more immediate threat, analysts say

You may also be interested in...



Generic Skelaxin Moves Closer As King Loses Patent Case; Last Hurdle Is FDA

Following a win in its patent case against King, Sandoz appears to have only one hurdle remaining before it can launch a generic of Skelaxin (metaxalone) - FDA approval of its ANDA

Generic Skelaxin Moves Closer As King Loses Patent Case; Last Hurdle Is FDA

Following a win in its patent case against King, Sandoz appears to have only one hurdle remaining before it can launch a generic of Skelaxin (metaxalone) - FDA approval of its ANDA

FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition

After FTC complaint, King opts to keep Avinza, and let patent-limited competitor go. But a new delay for key Alpharma product could hurt value of acquisition.

Related Content

Topics

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel